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A B S T R A C T
Symphytum officinale (comfrey), Tussilago farfara (coltsfoot) and Borago officinalis (borage) have long histories of
therapeutic use, but their safety has been questioned due to the presence of unsaturated pyrrolizidine alkaloids
(PAs). The evidence base underlying these concerns relies in part on case reports. This systematic review assesses
these case reports for their reliability to inform this debate.
Method: Study selection was restricted to case reports describing possible pyrrolizidine alkaloid related harm
and ingestion of comfrey, coltsfoot or borage. An extensive search of academic databases was conducted. Papers
meeting the criteria were critically appraised.
Results: The search resulted in 11 appropriate case reports, none of which involved borage. Nine reports were
assessed for causality and indicated some degree of association between the material ingested and the adverse
event. Lack of unequivocal identification of the species ingested compromised attribution and was a significant
source of uncertainty. Three levels of identity confusions were found; misidentification or substitution at the
level of the whole herb; omission of appropriate botanical identification and attribution of a specific PA to either
comfrey or coltsfoot when it is a constituent found in other plants of established toxicity.
Conclusion: These cases are an unreliable body of evidence on which to draw conclusions about the safety of the
oral consumption of Symphytum officinale and Tussilago farfara. Toxicological studies based on oral ingestion of
phytochemically-complex preparations of these herbs may be the most accurate methodology for assessing
clinical risk.
1. Introduction
This review focuses on three medicinal plants Symphytum officinale
(comfrey), Tussilago farfara (coltsfoot) and Borago officinalis (borage)
which have long histories of therapeutic use in Western herbal medicine
and like some 600 other plant species, contain pyrrolizidine alkaloids
(PAs) [1]. These compounds have been responsible for outbreaks of
acute poisoning in a number of communities when food, including bush
teas, were contaminated by varieties of Heliotropium, Crotalaria and
Senecio which contain 1,2 unsaturated PAs [2–4]. Unsaturated PAs
display no toxicity in their native form. Metabolic activation is a ne-
cessary step to exert toxicities and involves three main pathways – N-
oxidation to produce pyrrolizidine alkaloid N-oxides (PANOs);
hydrolysis to create necines and necic acids; and oxidation to form ei-
ther pyrrolic esters or dehydropyrrolizidine alkaloids (DHPAs) [5,6]. As
biotransformation of PAs occurs mostly in the liver, this organ is the
most affected by the toxic PA metabolites and in humans the char-
acteristic pathology associated with PA toxicity is hepatic veno-occlu-
sive disease (HVOD), although the lungs may also be affected leading to
pulmonary arterial hypertension [3,7]. Metabolites of at least five un-
saturated PAs (retrorsine, riddelliine, monocrotaline, lasiocarpine and
heliotrine) may form DNA adducts in the liver and have been associated
with hepatic carcinoma in rodent studies, but these have not to our
knowledge been identified in humans [2,6].
Pyrrolizidine alkaloids are also found in common foodstuffs. It is the
potential long-term health risks of low dose chronic exposure to this
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class of compounds from foods that is the cause of recent concern. The
European Medicines Agency (EMA) has identified milk, eggs, honey,
pollen products, grain and meat, and herbal products, including borage
and comfrey consumed in salads, as sources of PAs [8]. Understanding
this risk and estimating safe intakes is no simple task and a considerable
literature evidences the multiple variables involved. These variables
include differences in the toxicity of a given PA and associated meta-
bolites, differences in constituent PAs both within and between species,
differences in PA bioavailability from different preparations of the same
herb and individual responses in consumers which may relate to age,
gender and nutritional status [2,6,9,10]. Time of harvesting of plants is
also a factor as concentrations fluctuate during the growth cycle and
within plant part [11].
The assessments of risks to humans is largely based on mechanistic
toxicology and is heavily reliant on animal studies [9]. Whilst me-
chanistic data clearly demonstrates the potential for a causal relation-
ship between unsaturated PA metabolites and tissue damage [6], it can
also be expected that the degree of damage will vary depending upon
the unique structural characteristics of different unsaturated PAs [12],
and risk assessments involving Margins of Exposure (MOE) calculations
tend to base the calculations on only one structure, creating the po-
tential for substantial uncertainty [9]. However numerous researchers
refer to the available evidence from human case studies when reporting
or reviewing research on PAs, including case reports involving the
possible ingestion of comfrey or coltsfoot or borage (recent examples
include [13–15]). The research discussed here considers the validity of
the evidence derived only from case studies of these three herbs when
orally ingested. We do not review the mechanistic evidence or re-
commendations for levels of consumption from all sources of PAs, such
as those discussed by the European Food Safety Authority (EFSA) 2017
[9].
The EMA states that ‘according to the published literature, it is
possible that the average dietary daily intake might already be more
than the amounts of toxic, unsaturated PAs which are seen to be safe’
[16]. For these reasons PAs are the focus of ongoing international
concern, with regulatory authorities now attempting to determine safe
levels of intake. Low et al., point out that methods used for risk as-
sessment are highly conservative in that they utilise ‘worst case sce-
narios’ in relation to the assumptions made for lifetime daily exposure
of these foodstuffs [17]. However other authors suggest that the low
levels found in these common foodstuffs may be unrecognised causes of
a range of serious health concerns [9]. Chen and colleagues (2019) have
questioned the accuracy of the usual Margins of Exposure (MOE) risk
assessment method for determining risk of PAs in regards to herbal
medicines, as MOEs are typically based on the assumption of life-long
everyday use[10]. In their research, Chen et al. evaluated the potential
impact of regular short-term exposure of PA-containing plants prepared
as infusions and found a much-reduced level of risk. These researchers
believe such an approach is more representative of real-world use and
more accurately answer questions about the potential toxicity of typical
use of PA-containing herbal medicines, such as coltsfoot, comfrey, and
borage[10].
Comfrey, coltsfoot and borage are part of the armamentarium of the
Western herbalists. From the 17th century, Gerard [18] documents
their therapeutic action - coltsfoot for coughs, comfrey for internal and
external wounds, and borage which ‘always brings courage’. These
actions are still promoted 350 years later, albeit using terms which
reflect a more specific understanding of pathology, with the British
Herbal Pharmacopeia [19] recommending coltsfoot for bronchitis, lar-
yngitis and asthma and comfrey for gastric and duodenal ulcers and
colitis, as well as skin ulcers and wounds. At a similar time-period, 20th
century authors from Fernie to Weiss refer to the long-established use of
borage as a mood enhancer [20,66]. Interest in the phytopharmacology
of comfrey dates back at least to 1912 when Macalister reported the
presence of allantoin and its promoting effect on cell proliferation [21].
Recent research confirms, that apart from pyrrolizidine alkaloids,
comfrey's constituents include allantoin, phenolics, glycopeptides and
polysaccharides, while both in vitro and animal investigations demon-
strate antioxidant, anti-inflammatory and anti-microbial activity likely
to contribute to comfrey's efficacy [22–24].
Due to their PA content, these plants are increasingly seen as a
public health issue, and regulatory recommendations and restrictions
on their use have been put in place in many jurisdictions where they are
used [8]. In Australia comfrey, coltsfoot and borage cannot be legally
prescribed for internal use, in Germany and the Netherlands short-term
use of a prescribed dose is recommended (up to six weeks use at dose
levels of 1 μg/day), while the European Medicines Agency recommends
two weeks as the maximum duration of use when insufficient safety
data is established regarding a herbal medicine [16,17,25,26]. How-
ever, some herbalists are concerned about the extrapolation from in-
dividual constituents tested in vitro and in animal models to clinical
experience based on the use of whole plants [27].
While human data regarding long-term exposure is difficult to
gather, reports of suspected involvement of comfrey and coltsfoot in
this issue have been published since the mid-1980s. Two forms of
comfrey, Symphytum officinale and S. x uplandicum, have been im-
plicated in this controversy. S. officinale has been a valued medicinal
plant for many generations, and questions about its safety were not
raised until the 1980s. S. x uplandicum is a more recently introduced
plant associated with a range of benefits in agriculture and food.
Coltsfoot and borage have less popular and unique applications than
comfrey and have been less consistently researched. Borage leaves
contain unsaturated PAs, raising concerns in some parts of Europe
where these are used as a salad vegetable [16]. However, research also
indicates that its ingestion may be useful in gastric cancer prevention
[28,29–30].
Since no randomised controlled trials (RCTs) investigating the in-
ternal use of these three herbal medicines have been published to our
knowledge, assessment of their safety in humans relies, in part, on
observational methodologies. In the absence of rigorous cohort studies,
the best available evidence may be provided by case reports describing
adverse events in individuals ingesting comfrey, borage or coltsfoot
published in the peer-reviewed literature.
Whilst it is understood that randomised controlled trials are the
appropriate methodology for determining efficacy and formal dose-re-
sponse toxicology studies are required for determining safety, in-
formation gleaned from case studies is often used to inform safety-re-
lated decisions and policy. In the case of PAs, case reports of toxicity or
serious adverse events associated with PAs should best serve as signals
to conduct formal toxicology studies. Despite the limitations of case
reports, which make them unreliable to make safety determinations
especially of long term harm and potential carcinogenicity, they do
provide data on oral toxicity concerns which may be more clinically
relevant than the extrapolations made from in vitro and animal ex-
periments. The aim of this systematic review is to find all relevant case
reports and assess their reliability to inform the debate about the po-
tential toxicity of the oral consumption of comfrey, coltsfoot and bo-
rage.
2. Identification of studies
In early December 2017, two of the authors (IB and JAH) performed
a computer-based search of MEDLINE, CINAHL Plus, AMED, GreenFILE,
Health Source: Nursing/Academic Edition, PsycARTICLES, Psychology
and Behavioral Sciences Collection, PsycINFO, and EMBASE databases
(from inception to Nov 2017). The keyword search terms for these
specific PA-containing herbs and their alkaloids [“Borago”, “borage”,
“pyrrolizidine”, “lycopsamine”, “supinidine”, “amabiline”, “cynaus-
tine”, “Symphytum”, “comfrey”, “symphytine”, “7-acetyllycopsamine”,
“7-acetylintermedine”, “intermedine”, “lycopsamine”, “symlandine”,
“myoscorpine”, “echinatine”, “echimidine”, “heliosupine N-oxide”,
“heliotrine”, “lasiocarpine”, “viridiflorine”, “uplandicine”, “Tussilago”,
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“coltsfoot”, “senkirkine”, “senecionine”] were combined with keyword
search terms for PA-related harm [“liver”, “hepat*”, “megalocytosis”,
“venoocclusive disease”, “cirrhosis”, “carcinoma”, “adenoma”, “hyper-
plasia”, “mutagenicity”, “genotoxicity”, “safety”, “adverse events”,
“toxic*, “hepatotoxicity”, “drug induced liver injury”, “DILI”, “herb-
induced liver injury”, “HILI”, “intrinsic liver toxicity”] using the com-
bination term AND. The search term NOT [“Senecio OR Heliotropium”]
was added to reduce the number of irrelevant papers. Bibliographies of
case reports discussing the use of PA-containing medicinal plants and
potential toxicity, as well as previous reviews, and the authors' personal
libraries were hand-searched for additional references. There were no
language restrictions.
3. Method of data abstraction, inclusion and exclusion criteria
Study selection criteria were defined a priori and these are listed in
Table 1. Details of the search are described below.
The titles and abstracts of the articles found were screened by two
authors IB and JAH, and those that appeared to meet the criteria were
examined in further detail. Case reports that discussed the potential
toxic effect of the consumption of Borago officinalis, Symphytum offici-
nale or Tussilago farfara in humans were included. Reports were ab-
stracted and assessed by SJE, CA, SS and IB. Any discrepancies were
resolved by discussion of the paper or, if necessary, a third reviewer was
brought in to arbitrate. Key data abstracted for analysis included the
herb reported to be used, its form and dosage, who the prescriber was,
duration of treatment, patient details, patients' medical history, use of
concomitant medications by the patient, presenting symptom picture,
onset and course of symptoms, treatment and care received, in-
vestigatory findings, and authors causal attribution.
3.1. Quality assessment of case reports
The quality of each case report was assessed using the Quality of
Case Reports of Adverse Events Assessment Instrument (QCRAEI) [31].
Each report was scored out of 40 and ranked into one of five categories
from low quality through to high with a sixth category for reports
which were unable to be assessed. Details provided in Table 2 describe
these categories and those of the other assessment tools used. Papers
rated of moderate or good quality were then assessed in terms of
causality by both the RUCAM [32] and the WHO-UMC [33]. Authors of
published case reports were contacted via email or mail in an effort to
collect additional data on each case report.
4. Results
Searches of MEDLINE, CINAHL Plus, AMED, GreenFILE, Health
Source: Nursing/Academic Edition, PsycARTICLES, Psychology and
Behavioral Sciences Collection, and PsycINFO databases yielded a total
of 1110 citations. EMBASE discovered 1691 articles. Hand-searching
discovered an additional three articles. In total, 2804 reports were
screened. Papers were excluded if they were duplicates (720), animal
experiments (228), discussions on mechanisms of toxicity or pharma-
cokinetics (462), review articles and editorials (332), public literature
(28), reports on analytic chemistry (85), therapeutic intervention trials
(19), reports on other plant species (179), discussed accidental poi-
sonings from PA-containing foods or honey (59), were agricultural or
veterinary in nature (106), or were otherwise not relevant (508).
Seventy-eight papers were chosen to be examined in greater detail. We
excluded 67 of these papers, as they were not original case reports –
leaving 11 relevant case reports. A diagram illustrating the flow of ci-
tations through the screening process can be seen in Fig. 1.
Eleven case reports and letters published in the peer reviewed lit-
erature met the inclusion criteria [34–44]. The search revealed no case
reports of adverse events associated with borage. Three reports refer to
coltsfoot and eight to comfrey. These cases were published between
1985 and 2013 and reported adverse events considered to be associated
with the ingestion of either comfrey or coltsfoot in five countries (three
each from the UK and USA, two each from Switzerland and New
Zealand and one from Germany). Eight of the cases concerned hepatic
veno-occlusive disease (HVOD), two involved pulmonary pathology
(one with associated hepatic dysfunction) and one describes a case of
deep vein thrombosis and associated pulmonary embolism. The oldest
patient affected was 77 years, and the youngest was still in utero when
adverse impacts were detected. Three of the cases report a fatal adverse
event, five patients recovered, two patients became asymptomatic, but
were not fully recovered at the time of publication and no information
about recovery was provided in one case. Refer to Table 3 which pro-
vides key characteristics of the cases by herb, adverse event, outcome,
identification, dose and duration and concomitant medicines. Table 5
provides a more detailed case by case summary. None of the case re-
ports include the application of a validated adverse event or liver
toxicity criteria such as the Council of International Organizations of
Medical Sciences (CIOMS) Suspect Adverse Reactions [45].
4.1. Quality assessment of case reports of adverse events
Based on the QCRAEI, just one of the case reports which concerned
comfrey, met the criteria for ‘High’ quality reporting [44]. Four of the
reports about comfrey were rated ‘Upper Medium’ quality
[34,35,40,43], along with one relating to coltsfoot [36] while two case
reports about coltsfoot [39,42] and two about comfrey [37,41] were
considered ‘Medium low’ quality. Jones and Taylors [38] short letter
about comfrey was excluded from further assessment due its ‘Low’
quality. Given the sparsity of the data reporting on the consumption of
the relevant herbs, it was decided only to exclude the reports found to
be of low quality from further critical appraisal.
4.2. Application of causality assessments to the case reports and case studies
The WHO-UMC instrument was applied to the ten cases rated of
‘Medium low quality’ and above. The likelihood of the ingested plants
having a causative role in the adverse reaction was rated as ‘Probable’
in three cases [35,36,41] and ‘Possible’ in six [34,37,40,42–44], while
the case reported by Freshour et al., was found ‘Unassessable’ [39]. The
RUCAM was applied to the eight cases of appropriate quality where
hepatic involvement was reported. In five of the reports the ingested
plant material was rated as ‘Unlikely’ to cause the liver injury
[35–37,42,43]. In the cases reported by Miskelly & Goodyear [44] and
Rasenack et al. [41], herb-induced liver injury was rated as ‘Possible’.
One report by Ridker et al., was found ‘Unassessable’ [34]. The as-
sessment was carried out by four of the authors, independently (IB, SS,
SJE and CA). Disagreements were resolved by discussion. Details of the
assessments, including the herbs involved, can be viewed in Table 4.
Table 1
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Borago Other species
Borage Animal poisoning
Symphytum Veterinary
Comfrey Regulation
Tussilago Food contamination (including honey)
Coltsfoot Animal experiments
Peer reviewed papers Mechanisms of toxicity
Human case report Pharmacokinetics
Human case series Plant occurrence or prevalence
Review articles
Editorials
Otherwise not relevant
* Note: only genus and common names were used rather than species, to ensure
that cases on related species were captured.
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The causality assessments categorise the probability of association
into five ranks in the RUCAM and six in the WHO-UMC system (as
shown in Tables 2 and 4). None of the cases met the criteria for the first
rank in either rating method; ‘Certain’ (WHO-UMC) or ‘Highly prob-
able’ (RUCAM) or the second category of the RUCAM (‘Probable’).
However, eight reports were ranked as ‘Probable/Likely’, the second
rank in the WHO-UMC method, or in the third rank of either the
RUCAM (‘Possible’) or WHO-UMC ('Possible) (See Table 4).
The report by Freshour and colleagues [39] was rated of ‘Medium
low’ quality on the QCRAEI and was considered unassessable/un-
classifiable by the WHO-UMC method. There was no liver involvement
in this case, so it was not rated according to the RUCAM. The report by
Ridker and colleagues [34] was considered ‘unassessable’ when rated
on the RUCAM, although the reporting quality was rated ‘upper
medium’ and it was assessable by the WHO-UMC method. These find-
ings highlight the pros and cons of using a dual assessment system;
results were contradictory in some instances, although more of the
human data was assessed for causality in total, than if just one method
was relied upon.
There were no published case reports suggesting harm associated
with the ingestion of borage. To understand the possible role of
Symphytum officinale or Tussilago farfara in these cases, however, it is
necessary to review the source of the herbs and the data authenticating
the plant material. If the plants were authenticated in the course of the
treatment of the patient, this information was omitted in eight of the 11
case reports (including both the assessable cases involving coltsfoot)
and it was incomplete in all of them. Most of the reports omitted a
number of other details which explain why only one case [44] was
found to be of ‘High’ quality based on the QCRAEI. See Table 4 for
details.
Definitive botanical identification is not reported in the nine cases
where a causal association is considered a possibility when rated ac-
cording to RUCAM or the WHO-UMC (see Table 3) [34–37,40–44]. In
three cases, evidence of plants containing PAs found in the plant ma-
terial, or hepatic metabolites from biopsy or autopsy specimens was
published [34,36,41]. Additionally, patient case notes provided by the
author in the Schroff case provided this information [42].
4.2.1. Case reports referring to Borage (Borago officinalis)
No case reports referring to Borago officinalis were located in our
search.
4.2.2. Case reports referring to Coltsfoot (Tussilago farfara)
Both assessable case reports referring to Tussilago farfara identified
PAs among the plant material ingested. Fatal exposure to unsaturated
PA in utero is reported by Roulet et al., [36]. An expectorant herbal
formula consumed daily by the mother was analysed, along with au-
topsy specimens. The tea was purchased from a pharmacy and con-
tained ten ingredients, of which 9% w/w was Tussilago farfara. The
author reports that analysis of the tea by thin-layer chromatography
demonstrated a senecionine (and its N oxide) concentration of 0.6 mg/
kg dry weight of tea, however daily dosage of the tea was simply re-
ported as a single cup every day for the duration of the pregnancy.
Additionally, the reliability of this quantification is in doubt as the
stated analytical method was thin-layer chromatography with the full
procedure utilised not being described. Without the use of densito-
metry, thin-layer chromatography does not offer accurate quantifica-
tion [46].
Senecionine is found in Adenostyles alliariae and A. glabra [47,48]
Petasites hybridus [48,50] Senecio spp. [49] as well as Tussilago farfara
[50]. That Tussilago was the only, or primary source of senecionine in
the expectorant tea has since been questioned. In a letter to the editor
Table 2
Summary of the assessment instruments role, scoring systems and categories of the assessment instruments, the QCRAEI, the WHO-UMC and the RUCAM.
Instrument QCRAEI scoring WHO-UMC methodology RUCAM scoring
Role to assess: The quality of reporting of case in which an
adverse event occurred.
The association of herb with reported adverse
event by a qualitative method.
The association of herb with adverse event employing a
quantitative method using an algorithm.
Ranks High Certain Highly probable
1 29–40 ≥9
2 Upper medium 22–28 Probable Probable 6–8
3 Lower medium 15–21 Possible Possible 3–5
4 Low quality 0–14 Unlikely Unlikely 1–2
5 Excluded causality ≤ 0 Conditional/Unclassifiable Unassessable ≤ 0
6 Unassessable/Unclassifiable
QCRAEI Quality of Case Reports of Adverse Events Instrument Agbabiaka et al., 2008.
WHO-UMC World Health Organization Uppsala Monitoring Centre system for standardised case causality assessment (WHO-UMC).
RUCAM Roussel Uclaf Causality Assessment Method Danan & Teschke 2015.
Fig. 1. Flow of citations and articles through the phases of screening and
eligibility evaluation.
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published in Journal of Pediatrics in 1989 Spang reported that the tea
had been further researched by the local cantonal office and was found
to have ‘contained not only leaves and flowers of Tussilago farfara but also
roots of Petasites officinalis (Radix petasitidis)’ [51]. These two herbs
were also noted in the acute poisoning and development of HVOD in
the patient discussed in Schroff et al. [42]. In this case, leaves from
these two species were gathered in the wild by a Korean woman living
in Germany who thought she was picking a safe vegetable found in her
homeland (Eyer 2018 pers. comm). In the view of the toxicologist, the
Petasites was much more likely to have been responsible for her acute
symptoms than the Tussilago.
While it is likely that the adverse events described in these two cases
was caused by exposure to unsaturated PAs, the likelihood that the
ingested material included a species containing higher concentrations
Table 3
Summary case characteristics.
VOD Veno-occlusive disease; NR Not reported; PA Pyrrolizidine alkaloids.
Table 4
Assessment of case reports reporting an adverse event potentially associated with Symphytum officinalis or
Tussilago farfara, for quality and strength of association.
QCRAEI
Quality of repor!ng
Plant Author date WHO-UMC
Causality
RUCAM
Causality of HILI/DILI
High quality Comfrey Miskelly 1992 Possible Possible
Upper medium quality
Coltsfoot Roulet 1988 Probably/likely Unlikely
Comfrey
Ridker 1985 Possible Un-assessable
Weston 1987 Probable Unlikely
Yeong 1990 Possible     Unlikely
Gyorik 2009 Possible *
Low medium quality
Coltsfoot
Freshour 2012 
Un-assessable/ 
unclassifiable
Schroff 2013 Possible Unlikely
Comfrey
Bach 1989 Possible Unlikely
Rasenack 2003 Probably/Likely Possible
Low quality Comfrey Jones 1989
QCRAEI Quality of Case Reports of Adverse Events Instrument Agbabiaka et al., 2008.
WHO-UMC World Health Organization Uppsala Monitoring Centre system for standardised case causality as-
sessment WHO-UMC.
RUCAM Roussel Uclaf Causality Assessment Method Danan & Teschke 2015.
*No liver involvement.
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Table 5
Summary of case reports.
Patient 49 year old female [34]
Outcome Recovered
Location USA
Source 1 MU-16 (tea from Japan) - exact components not reported
Identification Tea bag from patient's supply analysed for PAs and pyrrolizidine N-oxide. Repeated 2 years later with specially purchased
MU-16.
Dose and duration 480 g of tea over 6 month period, estimated to provide total PA's 0.49–1.45 micrograms/kg of body weight per day.
Source 2 Comfrey-Pepsin capsules (from USA)
Identification Analysed for PA and pyrrolizidine N-oxide. Note: dry weight equivalent content of comfrey not declared, and powder
described as “white”
Does duration 6 capsules/day for 6 months estimated to provide total PA's 14.1 micrograms/kg body weight per day.
Combined dose and duration Calculated minimum total PA's per day 700–740 micrograms per day over multiple months.
Who prescribed? Not reported
Prescribed in response to: Not reported
Concomitant herbs and or medications Daily vitamin/mineral supplements (A, B C, E, K,Ca, Mg, K, Zn, Fe, lecithin); bovine adrenal extract; 3 cups chamomile
tea per week
No pharmaceutical medications.
Presenting symptoms, diagnostic details and course of
adverse event
Progressive swelling of abdomen & extremities over last 4 months
‘Several’ hospital admissions without diagnosis. Budd-Chiari syndrome diagnosed on biopsy which revealed centrilobular
necrosis and congestion. Hepatic venogram indicated moderate portal hypertension.
Side to side portacaval shunt: successfully reduced preportal pressure and ascites; long term follow up after discharge
revealed no serious problems except for transient bout of post-shunt encephalopathy attributed to ingestion of > 200 g
protein in 12 h period
Medical and or social history Two adult children.
Authors comment on causation Hepatic veno occlusive disease due to chronic low dose PA and pyrrolizidine N-oxide ingestion from MU-16 tea and
Comfrey-Pepsin capsules.
Patient 13 year old male [35]
Outcome Recovered from AE in context of pre-existing Crohn's disease
Location UK
Material ingested Comfrey tea
Identification Not reported
Dose and duration Not reported
About 3 years
Who prescribed? Naturopath
Prescribed in response to: Management of Crohn's disease following parental decision to discontinue. Pharmaceuticals reintroduced in response to
symptom exacerbation.
Concomitant herbs and or medications Prednisolone and sulphasalazine in acute exacerbations including at time of admission
Acupuncture
Presenting symptoms, diagnostic details and course of
adverse event
June 1986 presented with fatigue, diarrhoea and weight loss
July 1986 hospital admission fatigue, diarrhoea, weight loss, fever, abdominal pain. Examination revealed ascites and
tender hepatomegaly
Abnormal findings: Hb 117 g/L, bilirubin 26 mmol/L, AST 87 IU/L, albumin 27 g/L,
Diagnosis: thrombotic variant hepatic veno-occlusive disease Bx intimal thickening, sinusoidal distension, loss of
centrilobular hepatocytes
Patient responded well to spironolactone, salt restriction and bed rest. Bowel disease remained relatively inactive with
treatment with prednisolone and sulphsalazine, resumed school and ‘tolerably well on his medication’
Medical and or social history Diagnosis of Crohn's disease 1983
Authors comment on causation Hepatic veno-occlusive disease caused by the ingestion of comfrey tea in child with possibly increased susceptibility
due to sub optimal nutritional status secondary to Crohn's disease.
Patient Neonate female [36]
Outcome Death
Location Switzerland
Source Herbal tea containing Tussilago farfara 9% w/w of tea (9 other unnamed ingredients)a
Identification TLC: 0.6 mg senecionine (measured as N-oxide) per kg dry weight
Dose and duration A single cup daily through out pregnancy. Level of exposure to patient
relatively low (0.60 mg/kg dry weight)
Who prescribed? Not reported
Prescribed in response to: Expectorant tea purchased at a pharmacy.
Concomitant herbs and or medications Tea included 9 other unnamed herbs.
Presenting symptoms, diagnostic details and course of
adverse event
Normal pregnancy except pruritis of unknown origin since 4th month. Vaginal bleeding led to caesarean at 36 weeks.
Birth weight 2740 g. Within 5 days of birth developed jaundice, hepatomegaly, ascites, apathy. Serum levels of Liver
enzymes and bilirubin markedly elevated, level of some coagulation factors below normal. Liver biopsy day 27 of life:
centrilobular fibrosis, neovascularisation, iron deposition, widespread circumferential connective tissue occlusion of
small and medium hepatic veins. Patient died 38 days after birth. Autopsy confirmed hepatic veno-occlusive disease.
Medical and or social history Occasional cannabis and hallucinogenic mushrooms months before pregnancy.
Two siblings; normal births.
Mother no abnormalities.
Authors comment on causation Prolonged daily exposure to Tussilago farfara - led to cumulative toxicity causing veno-occlusive disease.
(continued on next page)
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Table 5 (continued)
Patient 49 year old female [34]
Patient No details [38]
Outcome Not reported
Location NZ
Source Comfrey tea
Identification Not reported
Dose and duration Not reported
Who prescribed? Self-prescribed
Prescribed in response to:
Concomitant herbs and or medications Other herbal teas
No pharmaceutical medications
Presenting symptoms, diagnostic details and course of
adverse event
Hepatic veno-occlusive disease
Medical and or social history Multiple sclerosis
Authors comment on causation Hepatic VOD due to comfrey tea.
Patient 47 year old female [37]
Outcome Symptoms resolved, but liver damage still evident at time of report.
Location USA
Source Comfrey tea and comfrey-pepsin tablets
Identification No identification reported.
Dose 10 cups of comfrey tea per day plus ‘handfuls’ of comfrey-pepsin tablets
Duration Over a year.
Who prescribed? Recommended by a homoeopathic doctor and purchased in a health food store in 1978
Prescribed in response to: Vague complaints of abdominal pain, fatigue and allergies.
Concomitant herbs and or medications None reported.
History and symptoms of Adverse event 1982 LFT revealed aminotransferase levels twice upper limit of normal. Ingestion of comfrey had stopped for 2–3 years.
1986 hepatomegaly and palmar erythema investigated. Serum ALP levels twice normal levels detected. December 1986
hospitalised with ‘massive’ ascites, hyponatremia and confusion. Patient responded to low sodium diet, but ascites
remained. A Denver shunt was inserted in January 1987. Fluid did not re-accumulate.
First biopsy: January 1987: diseased histology including perivenular fibrosis consistent with hepatic veno-occlusive
disease. 1988 Shunt removed.
Second biopsy: September 1989: pathological changes consistent with progressed veno-occlusive disease with further
fibrosis and areas of collapse with fibrous septa surrounding parenchyma nodules.
Medical and or social history No history of alcohol abuse or hepatitis
Authors comment on causation VOD due to comfrey tea and tablets
Patient 23 year old male [43]
Outcome Death
Location New Zealand
Source Not reported
Identification Not reported
Dose 4–5 young comfrey leaves, steamed daily
Duration 7–14 days
Who prescribed? Self-prescribed.
Prescribed in response to: Not reported.
Concomitant herbs and or medications No ethanol, marijuana, other medications or radiation exposure.
History and symptoms of Adverse event When hospitalised patient was emaciated, febrile, with gross ascites, pleural effusions, peripheral oedema and
hepatomegaly on percussion. LFT revealed multiple abnormalities. Two biopsies revealed multiple histological
abnormalities; severe portal hypertension confirmed by liver angiography. Treatment with diuretics was initiated. Liver
function continued to deteriorate. Patient developed a DVT in his left leg attributed to venous stasis secondary to tense
ascites and deteriorating renal function. An operation to insert a meso-atrial shunt failed to prevent further deterioration
and the patient died 7 days after the operation. Autopsy confirmed veno-occlusive disease.
Medical and or social history Vegetarian diet for 4 years characterised by ‘binge-eating’ single foods for days or weeks.
Three month history of influenza-like symptoms followed by malaise and night sweats. Peripheral oedema and abdominal
distension 3 weeks prior to hospital admission. No other pathology found on autopsy.
Authors comment on causation Temporal association indicative of causation due to ingestion of comfrey.
Patient 77 year old woman [44]
Outcome Recovered
Location UK
Source Comfrey tea
Identification Not reported
Dose and duration 1/2 tsp. three times a day where comfrey 6 parts in 27, 6 days out of 7, for 6 months
Who prescribed? Self-prescribed
Prescribed in response to: Unclear
Concomitant herbs and or medications Three herbal formulations; a bowel tonic, a nervine and BFC (Dr Christopher's Bone Flesh Cartilage) which contained 9
species including comfrey and skullcapb,
which was reported at 1 part in 27
(continued on next page)
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Table 5 (continued)
Patient 49 year old female [34]
Presenting symptoms, diagnostic details and course of
adverse event
Tiredness, anorexia and weight loss for 6 months, cough with green sputum for 3 months. Dark urine for a few weeks. On
examination moderately jaundiced, no pyrexia, hepatosplenomegaly or ascites. Chest clear on auscultation.
LFT revealed markedly elevated liver enzymes and bilirubin. Herbs continued. LFT unchanged 1 month later. Chest X-ray
found reticulonodular shadowing in the right mid-zone and base. Stopped herbs. LFT repeated in 2 weeks, significant
improvement revealed. Symptoms gradually improved over next 6 months. Liver function and chest X-ray were normal
after 4 months; and patient began to gain weight.
Medical and or social history Wasting disease
Authors comment on causation Close temporal association of ingestion of herbal medicines, particularly the comfrey and skullcap, to changes to liver
and lung, absence of other agents and cases reports and animal studies demonstrating veno-occlusive disease caused by
PAs.
Patient Foetus gestational age 27 weeks [41]
Outcome Death
Location Germany
Source Mixture of herbs imported from Turkey used in daily cooking.
Identification No botanical identification. GC and GC-Mass spectrometry found pyrrolizidine alkaloids consistent with comfrey and
heliotropium.
Dose and duration Estimated the quantity of PAs used in cooking to be 20–30 times the recommended limit of PA or 0.014–0.021 μg/kg
b.w./day.
Who prescribed? Self-prescribed
Prescribed in response to: Not reported
Concomitant herbs and or medications Several unidentified herbs in the mixture.
Presenting symptoms, diagnostic details and course of
adverse event
27 weeks gestation: Foetal skin oedema and polyhydramnios treated with corticosteroids; 30 weeks gestation: 2000 mL
amniocentesis;
31 weeks: Foetal ascites & skin oedema, intraperitoneal calcifications and hepatomegaly. Mother cholestasis with
pruritus. Mother treated with cholestyramine; 32 weeks: Mother dyspnoeic; bleeding from placental blood vessel,
2000 mL amniocentesis, and subsequent emergency caesarean; upon birth infant ventilated, multiple blood transfusions.
Death in 12 h.
Medical and or social history In first pregnancy caesarean section was performed postnatal development of the child was normal. 2nd pregnancy: L
sided renal atrophy led to nephrectomy and pregnancy spontaeously aborted in 8th week.
Authors comment on causation VOD seems to be caused by a herbal mixture used for daily cooking which contained pyrrolizidine alkaloids.
Patient 66 year old female [40]
Outcome Resolved
Location Switzerland
Source Mixture of herbs in a tea including Comfrey
Identification No
Dose One to one and a half litres a day of a tea containing nine herbs.
Duration Months
Who prescribed? Self
Prescribed in response to: Unclear
Concomitant herbs and or medications Another 8 unidentified herbs mixed into tea.
Presenting symptoms, diagnostic details and course of
adverse event
2006 hospitalised due to progressive dyspnoea. Blood gas analysis showed severe partial respiratory insufficiency. Liver
enzymes were mildly elevated. Pulmonary hypertension confirmed. CT scan of chest showed a mild polyserositis with
ground glass opacities in both lungs, not characteristic of pulmonary VOD according to two independent experts. At
follow up, requested to stop herbal tea. In 2008 admitted with right heart failure. After diuretic therapy, a CT scan of the
chest was repeated showing normal lung parenchyma with complete regression of previously reported opacities.
Medical and or social history History of arterial hypertension, non insulin dependent diabetes, moderate adiposity and mild renal insufficiency.
Authors comment on causation No other explanation being found, the authors conclude, the pulmonary hypertension to be ‘possibly’ caused by the
prolonged use of herbal remedies containing comfrey.
Patient 27 year old male [39]
Outcome Recovered
Location USA
Source Coltsfoot
Identification No
Dose Not reported
Duration Not reported
Who prescribed? Self
Prescribed in response to: No reported.
Concomitant herbs and or medications Nonsteroidal anti-inflammatories. Twelve other herbs consumed regularly are named.
Presenting symptoms, diagnostic details and course of
adverse event
Hospitalised for DVT in right calf and pulmonary embolism. Discontinued herbs. Treated effectively with anti-coagulants
which were to be continued on discharge.
Medical and or social history Right leg pain secondary to back injury 2 weeks prior to admission. Self-treated with bed rest for 14 days. Regular alcohol
consumption and 0.5 pack of cigarettes per day.
Authors comment on causation No direct causal link was identified, but other causes of DVT in a young and otherwise healthy male were excluded, so
the authors considered Coltsfoot as a possible causal agent.
Patient 63 year old female [42]
Outcome Slow recovery
(continued on next page)
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of PAs substantially weakens the attribution of causation to Tussilago
[51]. This is certainly borne out by the conclusion reached by the
toxicologist who made the assessment that P. albus carries a very high
risk of toxicity whereas the acute danger of one-off/singular intake of
Tussilago is very unlikely (Eyer 2018 pers.comm).
4.2.3. Case reports referring to Comfrey (Symphytum officinale)
In 2003, Rasenack et al., reported another fatal case, involving ex-
posure to PAs in utero, this time referring to comfrey [41]. This report
was found to be of ‘Low medium’ quality and was categorised in the
third rank (‘Possible’) in both the RUCAM and WHO-UMC methods. PAs
were found in a combination of herbs used daily in cooking and re-
portedly contained comfrey. Analysis of specimens taken from a biopsy
of the foetal liver revealed dehydrolycopsamine and dehy-
drointegerrimine, metabolites of lycopsamine and integerrimine, re-
spectively, while the PAs identified in the plant material were ly-
copsamine and “interrimine” and their O7-acetyl derivatives.
Lycopsamine is found in Borago officinalis, Symphytum officinale, S. as-
perum and S. x uplandicum [48] and rated of mildest PA toxicity [12,].
The reviewers were unable to identify a PA known as “interrimine”. The
authors of the case report state the PAs were consistent with helio-
tropium and comfrey, possibly suggesting echinatine, the only un-
saturated PA reported in both plants [52]. However, findings from the
foetal biopsy suggests integerrimine may have been present in the
cooking herbs. Integerrimine is a macrocyclic diester and thus a
member of what is considered to be the most potent class of PAs [12]
and is found in Petasites hybridus, Senecio spp. and Tussilago farfara, but
not in Symphytum spp. [53,50]. Without access to the original tox-
icology report it is not possible to clear up these discrepancies. How-
ever, while exposure to unsaturated PAs is undoubtedly the cause of the
tragic death reported, the definitive evidence of a causal role for Sym-
phytum or indeed Tussilago, is lacking.
Ridker and colleagues report a case of a 49-year-old female with
hepatic VOD who ingested a herbal tea (MU-16; manufactured in
Japan) and Comfrey-pepsin tablets (manufactured in the USA) [34].
This report was of ‘Upper middle’ quality on the QCRAEI. Both the tea
and tablets were analysed and the patients' exposure to PAs was esti-
mated at 14.6–15.6 μg/kg b.w./day for ~6 months. Assuming a 65 kg
bodyweight, this would equate to a daily dose of ~ 975 μg PAs. Given
the daily safe recommendation for PAs is generally considered to be
0.1 μg/day [9] (for the most potent PAs), this would equate to a long-
term safe dose of 10 μg/d for the PAs contained in comfrey, due to the
100-fold weaker activity of these PAs [12]. This level of ingestion
equates to nearly 100 times the recommended safe daily level for
chronic exposure based on relative PA toxicity [54]. However, no
specific alkaloid was named, the content of the Comfrey-pepsin capsule
was described as a white powder which does not seem consistent with a
root extract and the reviewers were unable to access further informa-
tion. This report was classified as ‘Possible’ by the WHO-UMC criteria,
but ‘Unlikely’ on the RUCAM. While the characteristic pathology is
strongly suggestive of exposure to unsaturated PAs, a direct relationship
to comfrey could not be definitively established.
The remaining four cases referring to comfrey include no evidence
of plant identification. These cases describe hepatic or pulmonary VOD
and include the fatal intoxication of a 23-year-old male after the in-
gestion of a 4–5 steamed leaves daily for 7 to 14 days [43]. In this case,
the patient is described as ‘emaciated’ with ‘gross ascites’ when hospi-
talised and to have eaten a vegetarian diet for 4 years characterised by
‘binge-eating’ single foods for days or weeks. It is therefore possible that
the patient's nutritional status may have been compromised, which may
have increased his vulnerability to toxic metabolites of PAs. Un-
saturated PAs display no toxicity in their native form and the majority
are excreted unchanged in the urine [6]. Biotransformation of the re-
maining 20% of ingested PAs occurs in the liver and it is this process
that results in the formation of toxic metabolites. Three main pathways
are involved: N-oxidation to produce pyrrolizidine alkaloid N-oxides
(PANOs); hydrolysis to create necines and necic acids; and oxidation to
form either pyrrolic esters or dehydropyrrolizidine alkaloids (DHPAs)
(5,6,). An important detoxification route for the highly reactive DHPAs
occurs via the formation of glutathione conjugates; promoting the
harmless elimination of these metabolites [6]. In vitro models have
clearly demonstrated that lowered glutathione status is associated with
greater hepatotoxicity from the ingestion of unsaturated PAs due to
prolonged exposure and increased concentrations of DHPAs [55–58].
Adequate protein and selenium intake are required for the synthesis of
the tripeptide glutathione [59]. The combination of unusual dietary
choices and emaciation, reported by Yeong, suggest the patient's glu-
tatione status may have been compromised increasing his susceptibility
to PA toxicity.
Clarity around the temporal association of ingestion of the steamed
leaves and the onset of the hepatic VOD is also unclear. The patient
described by Yeong [43] had a three-month history of influenza-like
symptoms followed by malaise and night sweats and both peripheral
oedema and abdominal distension three weeks prior to hospital ad-
mission while the steamed leaves were apparently eaten for just two
weeks prior to hospitalisation (Table 3 and Table 5). This case report
was categorised as ‘Unlikely’ using RUCAM, but ‘Possible’ when the
WHO-UMC method was applied. It is conceivable that the patient was
Table 5 (continued)
Patient 49 year old female [34]
Location Germany
Source Petasites and Tussilago
Identification (Unclear if the material tested was the material ingested. But some samples of Petasites and Tussilago were examined for PA
content found in case notes not publication)
Dose About 10 leaves, including both of the herbs (about 100 g)
Duration Consumed in one dose on a single occasion.
Who prescribed? Self
Prescribed in response to: Ingredients for a Korean recipe.
Concomitant herbs and or medications Not reported.
Presenting symptoms, diagnostic details and course of
adverse event
Symptom onset 3 h after consumption with nausea and vomiting. Hospitalised next day with abdominal pain and signs of
hepatic failure with highly elevated liver enzymes, low prothrombin and thrombocytopenia. Intense treatment for acute
poisoning in ICU. Liver biopsy at day 14 revealed veno-occlusive disease. Discharged from ICU at 24 days, still with
elevated liver enzymes. Mild ascites and similarly elevated liver enzymes present 3 months later when a liver biopsy
showed slight progression of the veno-occlusive liver disease.
Medical and or social history Recovery complicated by a fall which occurred in hospital and necessitated neurorehabilitation.
Authors comment on causation ‘Veno-occlusive liver-disease caused by pyrrolizidine alkaloid containing herbs may account for significant morbidity.’
a Spang (1989) reported that the tea the roots of Petasites officinalis, another plant containing unsaturated PA's were found in samples of this tea adds a level of
uncertainty to the connection between Tussilago and the death of the infant.
b More recent research has found no evidence that Skullcap (Scutellaria lateriflora) is hepatotoxic, but that it has frequently been substituted by the hepatotoxic
germander (including Teucrium canadensis & T. chamaedrys). These species are hepatotoxic (Engels 2009).
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particularly vulnerable to PAs, however this report does not establish a
causal relationship to Symphytum.
Weston et al., report the case of a male aged 13 who consumed
comfrey tea regularly for about three years as part of a therapeutic
regime to manage Crohn's disease [35]. The boy developed hepatic
VOD. Withdrawal of the tea was followed by improvement in liver
function. This report was classified as ‘Probable’ on the WHO-UMC
scale and ‘Possible’ on the RUCAM. While the identity of comfrey was
not confirmed, the association to PAs is clearly a strong possibility. The
patient was previously and at times concurrently, treated with pre-
dnisolone for his inflammatory bowel disease. It is possible that con-
current exposure to PA metabolites and a corticosteroid may have in-
creased the toxic potential of the PAs.
Corticosteroids are known to induce hepatic P450 3A activity [59].
A major detoxification route for PAs are initial hydrolysis and N-oxi-
dation to create PANOs. These metabolites can revert back into PAs and
then undergo oxidation into DHPAs and pyrrolic esters. This conversion
is carried out mostly by cytochrome P-450 (CYP450) monooxygenases,
specifically CYP3A and to a lesser degree CYP2B [5,6]. Consumption of
agents capable of inducing CYP3A activity concurrently with PAs would
be expected to substantially increase the production of highly reactive
DHPAs and pyrrolic esters. Therefore, it is possible that the combina-
tion of prednisolone with PA containing plants increased the production
of the toxic dehydro metabolites and exacerbated the adverse reaction.
The case reported by Miskelly et al., [44], (the only report rated as
of ‘High’ quality by the QCRAEI criteria) involved a 77-year-old female
with pulmonary VOD, who used several herbal tea blends for around six
months including comfrey. The case was ranked as ‘Probable’ using the
WHO-UMC method and ‘Possible” on RUCAM. Withdrawal of the herb
tea resulted in improvement of pulmonary symptoms and a drop in liver
enzyme values; the patient declined a liver biopsy. Miskelly names both
skullcap (presumably Scutellaria lateriflora) and comfrey and writes:
‘Both comfrey and skullcap may produce an acute hepatitis’ but only
comfrey is known to produce pulmonary lesions, and then only in rats.
This suggests that the pulmonary lesions were evidence of endothelial
hyperplasia and due to comfrey.’ [44]
The hepatotoxicity often attributed to skullcap is now known to be
caused by germander (including Teucrium canadensis & T. chamaedrys) –
common adulterants of skullcap. Germander is also known as pink
skullcap and has strong morphological similarities with skullcap [,60].
The herbal formula taken by this patient may well have included ger-
mander, not skullcap. Without identification of the herbs involved, it is
not possible to establish the role comfrey (or any other herb) may have
played in this case.
The case study reported by Bach et al., [37] is the only study that
reports hepatic VOD years after the consumption of the source of the PA
had stopped (See Table 5 for more details). The female involved was
47 years old when hospitalised with ascites and diagnosed with hepatic
VOD. The authors suggest the pathology was caused by her daily in-
gestion of ‘10 cups of comfrey tea’ and comfrey-pepsin tablets ‘by the
handful’ for roughly two years. Ridker et al., [34] also report a case in
which a patient took comfrey-pepsin tablets. In the case Bach reported,
four years after starting the comfrey, a liver function test (LFT) revealed
the patient had elevated liver enzymes. By this time the patient had
stopped taking comfrey for about two years. Four years after the raised
LFT, the patient had developed palmar erythema and hepatomegaly
with a liver biopsy the following year confirming hepatic VOD. This
patient had no history of hepatitis or alcohol problems. The comfrey tea
and tablets were sourced from a health food shop. Previous cases sug-
gest that an analysis of the plant material is the only way to rule out
other sources of PAs, however, it is likely that the tablets did contain
comfrey. Although the PAs in comfrey are considered to be of the
mildest potency, the exposure may have been both prolonged and
‘handfuls’ suggests a relatively high dose. When assessed using the
WHO-UMC method this case was categorised as ‘Possible’ and the
further review of the details confirms this assessment. When the
RUCAM was applied to the case, the ranking was ‘Unlikely’ reflecting a
lack of detail about concomitant medication and most health history.
5. Discussion
An extensive search of the literature revealed 11 case reports where
either comfrey or coltsfoot was considered by the authors to have a
possible role in the patients' adverse reaction. Reporting in one case was
of ‘Low’ quality (QCRAEI) and another report, which had no hepatic
involvement, was found unassessable (WHO-UMC). These cases were
not considered reliable enough to inform questions about safety.
Lack of adequate information about the botanical identification of
the plants consumed by the patient was a characteristic of the re-
maining case reports, although three of the reports did refer to PAs
found in ingested plants or biopsy material. This limits accurate attri-
bution of causality and the reliable assessment of the safety of comfrey
and coltsfoot.
Mistaken identity or substitution may have played a role in three
cases and was definitely involved in a fourth. The expectorant tea
containing Tussilago reported by Roulet et al., [36] may also have
contained Petasites [51]. It is plausible that germander, rather than
skullcap may have been found in the herb blends containing comfrey
taken by the patient in the case reported by Miskelly et al., [60]. Ra-
senack et al., [41], reported on the analysis of plant material and foetal
biopsy and autopsy samples in a case where comfrey was suspected.
However, some of the PAs named are not found in comfrey, but in
Petasites, Senecio spp. and in Tussilago [50]. Personal communication
and the full case notes, including the toxicology report make it clear
that the patient whose case was reported by Schroff et al., [42] picked
and cooked Tussilago and Petasites mistaking them for a plant native to
Korea. These examples emphasise the importance of undertaking and
documenting scrupulous identification procedures in relation to herbs
potentially associated with an adverse event.
In three of the cases, including one reported by Gyorik et al., [40]
where the adverse event involved pulmonary hypertension, patients
had a significant health history that may have made them more vul-
nerable to unsaturated PAs. One case involved a boy with Crohn's dis-
ease taking comfrey tea, at times with CYP3A-inducing steroid medi-
cations [35]; another women had several chronic conditions including
hypertension and type 2 diabetes mellitus and minor renal insufficiency
[40]; while a third patient is reported to have eaten an inadequate diet
for an extended period of time and described as emaciated [43]. In
these cases, the lack of definitive identification or confirmation of the
PAs present means it is challenging to assess causality.
These cases also highlight two of the biologically plausible ways in
which PAs may be more or less damaging in different populations and
individuals. As discussed in the review by Habs et al., [61], activation of
unsaturated PAs via CYP 3A4 enzymes results in the formation of the
highly reactive toxic metabolites, however further metabolism can also
result in detoxification, with glutathione appearing to be important in
this step [61]. Thus, concomitant medications or impaired glutathione
status may promote the synthesis, or slow the removal, of the toxic
metabolites from the liver. Agents that can induce CYP3A activity in-
clude Hypericum perforatum and a range of medications such as corti-
costeroids, aminoglutethimide, bexarotene, bosentan, carbamazepine,
dexamethasone, efavirenz, fosphenytoin, griseofulvin, modafinil, naf-
cillin, nevirapine, oxcarbazepine, phenobarbital, phenytoin, primidone,
rifabutin, rifampin, and rifapentine [62]. Co-administration of these
agents with medicinal herbs containing unsaturated PAs would thus be
expected to increase the risk of adverse events.
In two cases, the patients took comfrey-pepsin tablets, and in both
cases the dose may have been relatively high [34,37]. The history of the
patient reported by Bach and colleagues [37] follows the pattern of
slowly deteriorating liver function eventually diagnosed as HVOD,
several years after taking Symphytum for an extended period (about two
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years). This is the pattern observed in animal studies [2], but not so
clearly elucidated in any of the other cases. Both these patients had
HVOD which is characteristic of PA poisoning, but lacked confirmatory
evidence that the comfrey-pepsin tablets did contain PAs only from
Symphytum (along with the herbal tea, in the case reported by Ridker
et al.) [34].
Two of the cases reviewed involved in utero exposure to plants
containing PAs, both with fatal consequences [36,41]. Pyrrolizidine
alkaloids of higher lipophilicity including pyrrolizidine alkaloid N-
oxides (PANOs) are able to pass through the placenta and into breast-
milk [6,62]. It is for this reason that the German Federal Ministry of
Health has specifically prohibited the use of PA-containing herbal
medicines during pregnancy and lactation [54].
There has been a recent upsurge in global research into comfrey
which focuses primarily on the proliferative effects and anti-in-
flammatory activity, which has revealed a possible mechanism of action
for its anti-inflammatory effects [22,23]. Further, calls for additional
research investigating the root's antimicrobial potential [23,63] have
been made. A scoping review found moderate evidence for the external
application of comfrey root preparations in musculoskeletal pain and
healing abrasions. Although a high risk of bias was noted in some
studies, these results corroborate traditional use [64]. Identification of
anti-microbial activity and strong antioxidant capacity in some con-
stituents appears to support other traditional applications in the re-
spiratory and gastrointestinal tract, however these cannot be tested in
clinical trials due to regulatory restrictions and safety concerns.
It was beyond the scope of this systematic review to investigate or
critique in vitro or animal studies that have evaluated the potential
acute or chronic toxicity and carcinogenicity of unsaturated PAs in
general, or the specific PAs found in these three herbs. It should be
noted, however, that much of the toxicological research that has re-
sulted in the EMA recommendations was based on animal data using
the most potent class of PAs, given in isolation [9]. The EFSA Panel on
Contaminants in the Food Chain (CONTAM) conclude their recent
statement with recommendations for the collection of toxicological data
on the most commonly ingested PAs. The recommendations encourage
research which would allow a more accurate and nuanced under-
standing of the consequences of the consumption of the most commonly
ingested PAs. While such research is likely to provide a more reliable
basis for the assessment of the risks associated with comfrey, coltsfoot
and borage, toxicological studies based on the oral ingestion of phy-
tochemically complex preparations of these herbs may be the most
accurate methodology for assessing clinical risk.
6. Conclusion
Information gleaned from case studies is often used to inform safety-
related decisions and policy. However, there can be flaws in case stu-
dies that severely limit the reliability of their conclusions, and these
limitations may not be considered by those referencing them. This re-
view has highlighted many of the issues in these published case reports
of comfrey and coltsfoot. Our results were similar to case reports de-
tailing potential herbal medicine toxicity in other areas [65] where few
case reports were rated as high quality, and poor reporting in regards to
dosages and lack of herbal authentication were commonplace.
Case reports in the literature concerning the potential toxicity of
oral consumption of Symphytum officinale and Tussilago farfara in hu-
mans have been critically assessed in terms of quality of reporting and
for causality. No case reports concerning Borago officinalis were located.
Without adequate reporting of the botanical identity of the plants in-
volved it is not possible to reliably determine the degree to which these
herbs are associated with HVOD or other symptoms or to make defi-
nitive statements about the lack of safety of these herbs. The correct
authentication of the botanical identity of the plants involved in any
adverse event is vital to make meaningful and clinically translatable
causality assessments with implications for safe oral consumption of
these PA-containing herbs.
Based on these case reports, the evidence of harm caused by these
plants is weak. These cases are up to thirty years old. Insufficient detail
and inconsistent information make it difficult for clear assessments of
causality; nor is it possible to make such judgements with insufficient
information about concomitant medication and without full relevant
medical history. While many of the cases were possibly associated with
the ingestion of unsaturated PAs, they do not form a reliable body of
evidence on which to draw conclusions about the oral consumption of
the herbs at the centre of this review. Reference to these reports as
additional evidence of the toxicity of PAs or to provide human context
in a scientific study, implies a level of toxicity due to these herbs that is
yet to be unequivocally established. Retrospective cohort studies might
yet provide an estimate of the predictive risk of the ingestion of com-
frey, coltsfoot and borage in a clinical context. Further evidence could
be provided by toxicological studies based on traditional medicinal use.
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